Omeros Announces Q4 2025 Earnings and Key Business Updates
Omeros (OMER) reported strong financial results for Q4 2025, driven by a $237.6 million net gain from the sale of zaltenibart to Novo Nordisk in a deal worth up to $2.1 billion plus royalties. The company also secured FDA approval and launched YARTEMLEA (narsoplimab) for TA-TMA with positive initial market access.
Topics: FDA approval M&A pharmaceuticals reimbursement progress